TOLTERODINE TARTRATE (tolterodine tartrate) by Viatris (2) is receptors. Approved for overactive bladder with symptoms of urge urinary incontinence, urgency, frequency [see ] and 1 more indications. First approved in 2021.
Drug data last refreshed 21h ago
receptors. Both urinary bladder contraction and salivation are mediated via cholinergic muscarinic receptors. After oral administration, tolterodine is metabolized in the liver, resulting in the formation of 5-hydroxymethyl tolterodine (5-HMT), the major pharmacologically active metabolite. 5-HMT,…
Worked on TOLTERODINE TARTRATE at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Efficacy of Sanctura XR (Trospium Chloride) for Reducing Overactive Bladder Symptoms in Female Subjects Refractory to Detrol LA (Tolterodine Tartrate Extended Release) Daily
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)